Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBT-1 Dose Escalation in Healthy Volunteers and CKD Stage 3b-4
NCT03630029Phase 1Withdrawn
- Sponsor
- Renibus Therapeutics
- Start
- Sep 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of stannic protoporfin + iron sucrose in acute kidney injury (AKI) (5 arms), sponsored by Renibus Therapeutics. Primary endpoint: Effect of RBT-1 on biomarkers of cytoprotective activity at 7 days. Planned start Sep 2018; status: withdrawn.
02
Drugs
stannic protoporfin + iron sucrose
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT03630029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630029.